Testing tarlatamab for brain tumors that spread from small cell lung cancer
Official title: Tarlatamab for SCLC Brain Metastases
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a drug called tarlatamab in people whose small cell lung cancer has spread to the brain.
Read our full plain-language summary
What the trial team says
A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).
Key facts
- Registry number
- NCT07402343
- Stage of testing
- Phase 2
- Conditions studied
- Small Cell Lung Cancer, Brain Metastases, Adult
Where it is running
This trial lists 4 sites.
-
Netherlands
- The Netherlands Cancer Institute (Amsterdam)
- University Medical Center Groningen (Groningen)
- Maastricht UMC+ (Maastricht)
- Erasmus MC (Rotterdam)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.